Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease.
OBJECTIVE
Myeloperoxidase (MPO) polymorphism -463 has been related to higher cardiovascular risk. This study was conducted to test whether the MPO promoter polymorphism -463A/G and MPO plasma levels are associated with coronary artery disease (CAD) severity.


METHODS
Patients submitted to elective coronariography were enrolled, CAD severity was assessed and blood samples collected to identify the MPO polymorphism and its plasma levels.


RESULTS
Genotypes were determined in 118 patients. Among these patients, 12 (10%) were homozygous for AA, 69 (58%) for GG and 37 (32%) were heterozygous. Mean MPO plasma levels were 8.6+/-4.7 ng/mL for AA, 8.6+/-7.0 ng/mL for AG and 9.4+/-5.6 ng/mL for GG genotypes. The CAD severity was not associated with MPO genotypes (p=0.43), however, patients with higher CAD score presented higher MPO levels (p=0.02).


CONCLUSIONS
We found no association between MPO polymorphism and CAD severity, although a relation was observed for MPO plasma levels and extension of CAD.
Wainstein
Rodrigo V
RV
Cardiology Division of Hospital de Clinicas de Porto Alegre, Brazil. rodrigo.wainstein@uhn.on.ca
Wainstein
Marco V
MV
Ribeiro
Jorge P
JP
Dornelles
Laura V
LV
Tozzati
Paula
P
Ashton-Prolla
Patrícia
P
Ewald
Ingrid P
IP
Vietta
Giovana
G
Polanczyk
Carisi A
CA
D000368:Aged; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D003430:Cross-Sectional Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000097:blood / Q000235:genetics; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic / Q000235:genetics; D012307:Risk Factors; D012720:Severity of Illness Index
D009195:Peroxidase